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ABSTRACT 
Background: Compared to heart failure patients with higher systolic blood pressure 
(SBP), those with lower SBP have a worse prognosis.  To make matters worse, the 
latter patients often do not receive treatment with life-saving therapies that might 
lower blood pressure further. We examined the association between SBP and 
outcomes in the Prospective Comparison of angiotensin-receptor blocker-neprilysin 
inhibitor (ARNI) with an angiotensin converting enzyme (ACE) inhibitor to Determine 
Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF), as 
well as the effect of sacubitril/valsartan, compared with enalapril, according to 
baseline SBP. 
 
Methods: We analyzed the effect of treatment on SBP and on the primary composite 
outcome (cardiovascular death or heart failure hospitalization), its components and 
all-cause mortality. We examined baseline SBP as a categorical (<110, 110-<120, 
120-<130, 130-<140 and ≥140 mmHg) and continuous variable, as well as average 
in-trial SBP and time-updated SBP. 
 
Findings: All-cause and cardiovascular mortality rates were highest in patients with 
the lowest SBP whereas there was a U-shaped relationship between SBP and the 
rate of heart failure hospitalization. The benefit of sacubitril/valsartan over enalapril 
was consistent across all baseline SBP categories for all outcomes. For example, the 
sacubitril/valsartan versus enalapril hazard ratio for the primary endpoint was 0.88 
(95%CI 0.74-1.06) in patients with a baseline SBP <110 mmHg and 0.81 (0.65-1.02) 
for those with a SBP ≥140 mmHg (P for interaction=0.55). Symptomatic hypotension, 
study drug dose reduction and discontinuation were more frequent in patients with a 
lower SBP.   
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Interpretation: In PARADIGM-HF, patients with lower SBP at randomization, notably 
after tolerating full doses of both study drugs during a run-in period, were at higher 
risk but generally tolerated sacubitril/valsartan and had the same relative benefit over 
enalapril as patients with higher baseline SBP. 
 
Key words: heart failure, neprilysin, AT1-receptor, angiotensin, blood pressure  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 
 
INTRODUCTION 
Patients with heart failure often present with low systolic blood pressure (SBP) and 
because this is associated with poor outcomes, and because physicians are 
concerned about hypotension, they are often reluctant to prescribe medications likely 
to lower arterial pressure further, even if such treatments are known to improve 
prognosis (1-3). Recently, The Prospective Comparison of angiotensin-receptor 
blocker neprilysin inhibitor (ARNI) with an angiotensin converting enzyme (ACE) 
inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial 
(PARADIGM-HF) randomized 8399 patients in 47 countries to treatment with 
enalapril 10 mg twice daily or with sacubitril/valsartan (formerly known as LCZ696) 
200 mg twice daily (4,5). Compared with enalapril, sacubitril/valsartan reduced the 
primary composite endpoint of cardiovascular death or heart failure hospitalization by 
20% (5). However, because sacubitril/valsartan not only blocks the renin angiotensin 
system, but also enhances the activity of vasoactive substances such as the 
natriuretic peptides and bradykinin, it reduces blood pressure more than an ACE 
inhibitor or ARB. Because this may cause concern among physicians treating 
patients with a low SBP, we analyzed the efficacy and safety of sacubitril/valsartan, 
compared with enalapril, according to baseline SBP, and SBP after randomization, in 
PARADIGM-HF.   
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METHODS 
The design (4) and the primary results (5,6) have been published. Patients enrolled 
were in New York Heart Association (NYHA) class II-IV with an ejection fraction 
≤40% (changed to ≤35% after amendment) and a plasma B-type natriuretic peptide 
(BNP) ≥150 pg/ml or N-terminal proBNP (NT-proBNP) ≥600 pg/ml (or for patients 
with a heart failure hospitalization within 12 months, BNP ≥100 pg/ml or NT-proBNP 
≥400 pg/ml). In a run-in period, patients were pre-exposed to an ACE-inhibitor or an 
angiotensin receptor blocker (ARB) at a dose equivalent to enalapril 10 mg daily for 
at least 4 weeks before screening. Furthermore, patients had to be on a stable dose 
of a beta blocker (if tolerated) and a mineralocorticoid antagonist (if indicated). 
Patients with intolerance to ACE-inhibitors or ARBs, with symptomatic hypotension or 
a systolic blood pressure <100 mmHg at screening/<95 mmHg at randomization, an 
estimated glomerular filtration rate (GFR) <30 ml/min/1.73 m2 or a decrease in eGFR 
of more than 25% (amended to 35%) between screening and randomization, a serum 
potassium >5.2 mmol/l at screening (or >5.4 mmol/l at randomization) and a history 
of angioedema were excluded.  
 
Study procedures  
At entry, treatment with an ACE-inhibitor or ARB was stopped (other treatments were 
continued). Patients first received enalapril 10 mg twice daily for 2 weeks (single-
blind) and then sacubitril/valsartan (single-blind) for an additional 3-6 weeks, initially 
at 100 mg twice daily and then 200 mg twice daily. Patients completing both phases 
of the active run-in period were assigned in a 1:1 ratio to double-blind treatment with 
either enalapril 10 mg twice daily or sacubitril/valsartan 200 mg twice daily. If 
symptomatic hypotension occurred, the protocol recommended reduction in the dose 
or discontinuation of concomitantly administered blood pressure lowering drugs (e.g. 
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nitrates and diuretics), except guideline-recommended disease-modifying drugs for 
heart failure (e.g. beta-blockers and mineralocorticoid receptor antagonists). 
However, the study drug could also be reduced in dose, or temporarily discontinued, 
if hypotension (or other adverse effects) occurred. BP was recorded at every visit 
using a standard sphygmomanometer with an appropriately sized cuff at the non-
dominant arm in the sitting position after 5 minutes of rest. During the trial, the 
occurrence of hypotension was enquired about at each study visit by means of a 
question on the case report form. 
 
Study outcomes  
The main outcomes of interest were the primary endpoint (composite of 
cardiovascular death and heart failure hospitalization) of the trial and its components, 
as well as two of the secondary outcomes, all-cause death and the clinical summary 
score of the Kansas City Cardiomyopathy Questionnaire (KCCQ).  
 
SBP analyses 
We analyzed change in SBP from baseline according to treatment assignment, 
relationship between SBP and clinical outcomes, and effect of study drug on 
outcomes according to SBP. Specifically, we analyzed change in SBP from baseline 
to 4 months, and over the whole duration of follow-up, as well as time-updated SBP 
during follow-up. We analyzed SBP at baseline by category (<110 mmHg, 110-<120 
mmHg, 120-<130 mmHg, 130-<140 mmHg and ≥140 mmHg) and as a continuous 
measure. We examined the association between baseline SBP, change in SBP and 
time-updated SBP and the primary endpoint and secondary endpoints described 
above. Finally, we explored the effect of sacubitril/valsartan, compared with enalapril, 
on these endpoints according to baseline SBP category and SBP analyzed as a 
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continuous measure. Adverse events according to baseline SBP category are also 
reported.  
 
Statistical analysis  
The effect of sacubitril/valsartan, compared with that of enalapril, on each outcome of 
interest, according to SBP category, was examined using Cox proportional hazards 
regression models. Restricted cubic spline analysis was used to examine the effect of 
treatment according to SBP modeled as a continuous variable. The interaction 
between continuous SBP and treatment group on the occurrence of the pre-specified 
safety outcomes was tested in a logistic regression model with a term for interaction 
between SBP and treatment. All analyses were conducted using R version 3.1.2 . A 
p-value of <0.05 was considered statistically significant.  
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RESULTS 
Overall, 8399 patients were included in the analysis. Table 1 shows the baseline 
characteristics of patients in the different SBP categories. Compared to patients with 
higher SBP, those with lower SBP were younger, more often male and less likely to 
have an ischemic etiology or a history of diabetes or hypertension. Patients with a 
lower SBP also had a lower ejection fraction and slightly lower heart rate and body 
mass index. Notably, NTproBNP and eGFR did not differ substantially across SBP 
category. Patients with a lower SBP were more often treated with digoxin (not 
accounted for by differences in prevalence of atrial fibrillation), a MRA and devices.  
 
Effects of enalapril and sacubitril/valsartan on blood pressure  
Figure 1 summarizes the change in SBP at 4 months in each treatment group. In 
both groups, SBP increased in patients with the lowest baseline SBP and decreased 
in those starting with a higher SBP (Figure 1), a finding that was similar over the 
whole follow-up period (Supplement Figure 1). However, the increase in SBP with 
sacubitril/valsartan was less than in the enalapril group and the decrease in SBP with 
sacubitril/valsartan greater than with enalapril (Supplement Figure 2A), meaning that 
post-randomization SBP was lower in the sacubitril/valsartan than in the enalapril 
group across the SBP range (Supplement Figure 2B).  At 4 months SBP was 
approximately 4-6 mmHg lower in the sacubitril/valsartan group across the SBP 
categories (Supplement Figure 2B).  
 
Relationship between baseline SBP and cardiovascular outcomes  
Figure 2 summarizes the relationship between baseline SBP category and clinical 
outcome (SBP <110 mmHg used as the reference group, hazard ratio=1). Risk was 
lower for all outcomes in the higher SBP categories although less clearly in patients 
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with a baseline SBP ≥140 mmHg. In order to investigate this potentially non-linear 
relationship further, we carried out restricted cubic spline analyses of the association 
between SBP and the outcomes of interest. Examination of these confirmed that the 
risk of death (all-cause and cardiovascular) and the risk of heart failure hospitalization 
was higher in patients with a lower SBP (Figure 3). However, above a SBP of 
approximately 120mmHg the relationship between SBP and both types of death was 
flat, whereas the risk of heart failure hospitalization was greater in patients with a 
higher SBP (>140 mmHg approximately) i.e. there was a U-shaped relationship 
between SBP and heart failure hospitalization. The shape of the relationship between 
SBP and outcomes was similar in the time-updated covariate analyses (using the last 
SBP measurement at the time point closest to an event or at the end of the study) 
(Supplement Figure 3).  
 
Beneficial effects of sacubitril/valsartan compared with enalapril according to 
baseline SBP  
Figure 4 shows the primary endpoint rates by baseline SBP category, according to 
treatment assignment. Compared with enalapril, sacubitril/valsartan reduced the risk 
of the primary endpoint across all SBP categories (p-value for SBP-treatment 
interaction=0.55). Similar findings were observed for cardiovascular death, heart 
failure hospitalization and all-cause death (Table 2 and Supplement Figures 4-6).  
The effects of sacubitril/valsartan, compared with enalapril, on the primary and other 
outcomes, adjusting for SBP, are summarized in Supplement Figure 7. The effect of 
treatment was adjusted in a variety of models all of which included age and sex. The 
models took account of baseline SBP (as a continuous measure), baseline SBP 
category, average SBP including baseline and all follow-up visits, baseline and post-
randomization SBP updated to the time of an event and time-updated SBP group. 
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These adjustments did not change the benefit of sacubitril/valsartan over enalapril. 
Furthermore, we analyzed patients with low blood pressure at baseline (<= 100 mm 
Hg vs. >100 mmHg), who further dropped or increased with SBP on treatment. 
Supplement Figure 8 shows all cause death (A, sacubitril/valsartan; B, enalapril) and 
the primary endpoint (C, sacubitril/valsartan; D, enalapril) for low (<= 100 mmHg) or 
high (> 100 mmHg) SBP at baseline or penultimate. Low SBP at penultimate was 
clearly associated with high total death on enalapril with lower rates on 
sacubitril/valsartan. Similar results were obtained with the primary end point 
(Supplement Figure 8 C,D). Furthermore, we pooled patients and explored high or 
less (> or < 100 mmHg) at 4 months after randomization to enalapril or 
sacubitril/valsartan (Supplement Figure 9). The event rates were higher on 
sacubitril/valsartan and on enalapril when SBP was low. There were less event rates 
on sacubitril/valsartan than on enalapril in either SBP group.  
 
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score  
At each visit in each SBP group, the portion of patients having a fall of five or more 
units in the KCCQ clinical summary score was smaller in the sacubitril/valsartan 
group than in the enalapril group (Table 3). The benefit of sacubitril/valsartan over 
enalapril in preventing worsening of KCCQ was consistent across SBP groups when 
adjusted for baseline variables (p for interaction 0.47). 
 
Pre-specified safety assessments according to baseline SBP and treatment 
assignment 
Table 4 summarizes the occurrence of the pre-specified safety outcomes according 
to SBP at baseline. Symptomatic hypotension and hypotensive symptoms with a SBP 
<90mmHg were more frequent in the group starting with a SBP <110 mmHg, 
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irrespective of treatment allocation, although these adverse effects occurred more 
often in the sacubitril/valsartan group than in the enalapril group. The other adverse 
effects of interest, including elevation in serum creatinine concentration, did not have 
an obvious relationship with baseline SBP. Study-drug dose reduction and 
discontinuation for hypotension was more frequent in patients with a low SBP at 
baseline (Figure 5). These rates were also nominally higher for sacubitril/valsartan 
than for enalapril. However, only 1.3% (n=13) of patients discontinued 
sacubitril/valsartan compared to 9 (1.0%) on enalapril in those with SBP <110 mmHg. 
The number was < 1% in all other baseline SBP groups for both drugs.  
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DISCUSSION 
In this study, we have confirmed and extended prior findings about the relationship 
between blood pressure and outcomes in patients with heart failure and reduced 
ejection fraction (HF-REF), albeit in a selected group which had tolerated full-dose 
enalapril and sacubitril/valsartan during an active run-in period before randomization. 
We have also described the safety and efficacy of sacubitril/valsartan, compared with 
enalapril, across the range of blood pressure in PARADIGM-HF. Several studies 
have shown that patients with low SBP have a worse prognosis than those with 
higher SBP (1-3).  
 
Because patients with low SBP were often undertreated with disease-modifying 
therapy, previous studies left open the possibility that sub-optimal treatment, rather 
than SBP per se, accounted for, or at least contributed to, the poor outcomes in 
these patients. By design, all patients randomized in PARADIGM-HF (5-6) were 
treated with an evidence-based dose of renin-angiotensin system blocker and more 
than 90% also received a beta-blocker. Despite this, and greater use of 
mineralocorticoid receptor antagonists and digoxin, patients with a low BP still had 
worse outcomes than those with a higher SBP. It is not clear why this was, as 
patients with low baseline SBP in PARADIGM-HF did not have evidence suggesting 
more advanced disease. Specifically, patients with lower SBP at baseline were 
younger and did not have worse NYHA class and KCCQ scores or notably higher 
natriuretic peptide or lower eGFR levels. LVEF was only slightly lower in patients with 
lower SBP. Therefore, low SBP is a marker of poor outcome. Whether low SBP  
identifies patients with more advanced disease and comorbidities and is not 
necessarily harmful in itself, at least above a certain threshold, could be speculated 
but cannot be proven. 
14 
 
  
 
Interpretation of the relationship between SBP and outcomes in previous studies has 
also been hampered by the statistical phenomenon of “regression to the mean” 
whereby SBP was consistently noted to decrease after randomization in patients with 
a higher starting SBP and to increase in those with a lower baseline SBP (CHARM 
(7), Val-HeFT (8), A-HeFT (9) and COPERNICUS(10)). Potentially, this may have 
diluted the relationship between baseline SBP and outcomes. For this reason, we 
also conducted a time-updated covariate analyses, using the last SBP measurement 
at the time point closest to an event or at the end of the study. Finally, patients with  a 
low SBP on treatment (< 100mmHg) had worse outcomes compared to those at 
higher SBP (>100 mmHg), but the event rate was lower on sacubitril/valsartan 
compared to enalapril. Whether or to what extend low SBP at baseline, spontaneous 
decline or drug-induced effects are associated if not involved with poor outcome 
cannot be clarified.  These findings  strengthened the relationship between SBP and 
outcome, reinforcing the importance of SBP as a predictor of outcome. 
 
The third extension of prior findings is our demonstration of a U-shaped relationship 
between SBP and heart failure hospitalization (and therefore the composite of 
cardiovascular death or heart failure hospitalization) whereby higher hospitalization 
rates were observed at both ends of the SBP range included in PARADIGM-HF (5). 
This was quite different than for mortality (cardiovascular or all-cause) where the 
relationship between SBP and the risk of death was flat above a SBP of 
approximately 120mmHg.  Indeed, it was notable that 14% of patients in PARADIGM-
HF had a SBP above the threshold for treatment of hypertension (i.e. those in the 
≥140 mmHg category, with a mean SBP of 148 mmHg), despite their treatment with 
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multiple hypotensive medications. Why the rate of hospitalization of heart failure was 
higher in patients with a SBP ≥140 mmHg, but mortality was not, is unclear.  
 
Sacubitril/valsartan improved clinical outcomes, compared with enalapril, across the 
range of SBP studied. This treatment benefit was robust, persisting after adjustment 
for SBP at baseline, average SBP during follow-up and time-updated SBP, the latter, 
as explained above, strengthening the relationship between low SBP and poor 
outcomes. Consequently, even in patients with a persistently low SBP after 
treatment, sacubitril/valsartan was superior to enalapril in reducing mortality and 
morbidity. 
 
In these analyses, patients with a low baseline SBP are those of most interest given 
their greater risk of death and hospitalization and the concern physicians often have 
about using blood pressure lowering drugs in them. Indeed, because of this concern, 
patients with a low SBP have even been excluded from many key trials in heart 
failure (CIBIS-2, MERIT-HF). PARADIGM-HF enrolled a large number (n=1747) of 
patients with a low SBP (1747 <110, 1173 <105 and 309 <100mmHg), comparing 
favorably with other major trials that have examined the safety and tolerability of 
blood pressure reducing drugs in heart failure, including Val-HeFT (1156 patients 
≤110 mmHg), COPERNICUS (396 <105 mmHg), and CHARM (385 ≤100 
mmHg).7,8,10 Patients in the lowest SBP category in PARADIGM-HF attained the 
same relative magnitude of benefit from sacubitril/valsartan as patients in the trial 
overall. Consequently, because such patients are at higher risk of adverse clinical 
outcomes, the same relative risk reduction with sacubitril/valsartan is expected to 
give a greater absolute risk reduction – of the order of a 3-4 fewer fatal and non-fatal 
events per 1000 patient years of treatment. This principle is true for all disease 
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modifying neurohumoral and vasodilating drugs studied to date yet, paradoxically, as 
mentioned earlier, these sicker patients with potentially more to gain are the least 
likely to be treated. Inevitably, however, this additional benefit comes at a cost. As in 
prior studies, patients with a low baseline SBP have more hypotension-related 
adverse effects reported, irrespective of treatment allocation (even if assigned to 
placebo). This was also observed in PARADIGM-HF, although the proportion of 
patients assigned to sacubitril/valsartan and experiencing symptoms of hypotension 
and a SBP <90 mmHg or discontinuing study drug for hypotension was not large. 
However, this finding must be interpreted in light of the study design (with sequential 
active run-in periods – enalapril followed by sacubitril/valsartan). Specifically, of 
10513 patients treated with enalapril over a median duration of 15 [IQR 14-21] days 
run-in 1102 (10.5%) discontinued the study for any reason (including administrative 
reasons and withdrawal of consent). For sacubitril/valsartan, of 9419 patients treated 
over a median duration of 29 [IQR 26-35] days run-in 977 (10.4%) discontinued the 
study. In the two periods, 146 and 164 patients respectively, discontinued for an 
adverse effect related to hypotension. A recent analysis, using inverse probability 
weighting to adjust for variables associated with discontinuation during the run-in, 
showed no significant diminution of the benefit of sacubitril/valsartan over enalapril 
with respect to the key outcomes cardiovascular death, heart failure hospitalization 
and all-cause death was shown (11). Furthermore, in another study without an active 
run-in period (TITRATION), up to 84% of patients tolerated the introduction of 
sacubitril/valsartan without interruption or down-titration (12).  
 
Some limitations of our study need to be acknowledged. This was a post-hoc 
exploratory analysis and patients were not randomized according to SBP. All 
randomized patients had demonstrated toleration of both enalapril 10mg twice daily 
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followed by sacubitril/valsartan 200 mg twice daily. Patients could not be randomized 
if their SBP was <95 mmHg or they had symptoms of hypotension. 
 
In conclusion, we have confirmed that low SBP is associated with worse outcomes in 
HF-REF and have shown that, if an individual could tolerate sacubitril/valsartan, 
(notably after pre-exposure to the maximal dose in a run-in phase) it was beneficial 
across the range of SBP included in PARADIGM-HF in patients taking other guideline 
recommended therapies (11). Compared to patients with a higher SBP, those with 
lower SBP may obtain greater absolute benefits from sacubitril/valsartan but at the 
expense of more hypotension-related adverse effects.   
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LEGENDS TO FIGURES 
 
Figure 1  
Change in systolic blood pressure at 4 months according to systolic blood pressure 
categories at baseline enalapril (left) and LCZ696 (right) treated patients. Patients 
with extreme increases or decreases in these groups are depicted separately.  
 
Figure 2  
Adjusted hazard ratios for the primary endpoint (A), cardiovascular death (B), heart 
failure hospitalization (C) and total death (D) according to systolic blood pressure at 
baseline in all patients. The group with systolic blood pressure <110 mmHg is given 
as a reference (=1).  
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Figure 3  
Hazard ratio for the primary outcome (A), cardiovascular death (B), heart failure 
hospitalization (C) and all-cause death (D) in all patients (left), on enalapril (middle) 
and on LCZ696 (right) according to systolic blood pressure at baseline.  
 
Figure 4  
Kaplan Meier event curves for the primary endpoint <110 mmHg (A), 110-<120 
mmHg (B), 120-<130 mmHg (C), 130-<140mmHg (D) and >140 mmHg (E) on 
enalapril and LCZ696. Cox regression p-values and the interaction p-value are given.  
 
Figure 5 
Hypotension (A), rate of dose adjustments (B) and rate of dose adjustments + 
discontinuation of study drugs (C) on enalapril (left) or LCZ696.  
 
Supplement Figure 1  
Systolic blood pressure change from baseline over time in all patients (A), on 
enalapril (B) and on LCZ696 (C) according to baseline blood pressure.  
 
Supplement Figure 2  
Systolic blood pressure after 4 months according to baseline systolic blood pressure 
(A) and change in systolic blood pressure at 4 months according to baseline systolic 
blood pressure (B). Lines of identity (A) and neutrality (B) are depicted by the dotted 
lines.  
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Supplement Figure 3   
Adjusted hazard ratios for the primary endpoint (A), cardiovascular death (B), heart 
failure hospitalization (C) and total death (D) according to time-updated systolic blood 
pressure in all patients. The group with systolic blood pressure <110 mmHg is given 
as reference (=1). 
 
Supplement Figure 4  
Kaplan Meier event curves for cardiovascular death by baseline SBP groups  <110 
mmHg (A), 110-<120 mmHg (B), 120-<130 mmHg (C), 130-<140mmHg (D) and >140 
mmHg (E) on enalapril and LCZ696. Cox regression p-values and the interaction p-
value are given. 
 
Supplement Figure 5  
Kaplan Meier event curves for heart failure hospitalization by baseline SBP groups  
<110 mmHg (A), 110-<120 mmHg (B), 120-<130 mmHg (C), 130-<140mmHg (D) and 
>140 mmHg (E) on enalapril and LCZ696. Cox regression p-values and the 
interaction p-value are given. 
 
Supplement Figure 6  
Kaplan Meier event curves for total death by baseline SBP groups  <110 mmHg (A), 
110-<120 mmHg (B), 120-<130 mmHg (C), 130-<140mmHg (D) and >140 mmHg (E) 
on enalapril and LCZ696. Cox regression p-values and the interaction p-value are 
given. 
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Supplement Figure 7 
Hazard ratios showing the treatment effect of LCZ696 on the primary endpoint (A), 
cardiovascular death (B), heart failure hospitalization (C) and total death (D) adjusted 
for systolic blood pressure at baseline (all individual patients) (LCZ base_num) by 
different baseline blood pressure groups (LCZ base_grp) by the average of systolic 
blood pressure at all visits (LCZ Avg_num) and time-updated blood pressure by all 
individuals (LCZ update_num) and updated systolic blood pressure by groups (LCZ 
update_grp). The risk on enalapril is given as reference. 
 
Supplement Figure 8  
Kaplan Meier event curves for all cause death (A,B) and the primary endpoint (C,D) 
on sacubitril/valsartan (A,C) or enalapril (B,D) by low systolic blood pressure (SBP) at 
baseline (<=100 mmHg (low) versus >100 mmHg, high) and low or high on 
treatment.  
 
Supplement Figure 9  
Kaplan Meier event curves for the primary endpoint (A,B), cardiovascular death (C,D) 
and heart failure hospitalization (E,F) on sacubitril/valsartan (left, A,C,E) or enalapril 
(right, B,D,F) with a blood pressure performance above (blue, high) or below (red, 
low) 100 mmHg at 4 months.  
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Table 1 Baseline characteristics according to systolic blood pressure 
 
Variable Statistic 
<110 
(N = 1747) 
110-<120 
(N = 1931) 
120-<130 
(N = 2059) 
130-<140 
(N = 1477) 
≥140 
(N = 1185) 
P value 
Sacubitril/valsartan N (%) 834 (47.7%) 990 (51.3%) 1041 (50.6%) 731 (49.5%) 591 (49.9%) 0.2714 
Age Mean (SD) 61.30 (12.01) 62.81 (11.58) 64.34 (11.17) 65.65 (10.36) 65.83 (10.89) <0.0001 
Sex Female N (%) 335 (19%) 389 (20%) 441 (21%) 359 (24%) 308 (26%) <0.0001 
Race White N (%) 941 (53.9%) 1218 (63.1%) 1441 (70.0%) 1070 (72.4%) 874 (73.8%) <0.0001 
Black N (%) 111 ( 6.4%) 101 ( 5.2%) 92 ( 4.5%) 54 ( 3.7%) 70 ( 5.9%) 0.0039 
Asian N (%) 453 (25.9%) 392 (20.3%) 320 (15.5%) 205 (13.9%) 139 (11.7%) <0.0001 
Other N (%) 242 (13.9%) 220 (11.4%) 206 (10.0%) 148 (10.0%) 102 ( 8.6%) <0.0001 
Region North 
American 
N (%) 181 (10.4%) 165 ( 8.5%) 137 ( 6.7%) 67 ( 4.5%) 52 ( 4.4%) <0.0001 
Latin America N (%) 357 (20.4%) 381 (19.7%) 331 (16.1%) 212 (14.4%) 152 (12.8%) <0.0001 
Western Europe N (%) 510 (29.2%) 467 (24.2%) 442 (21.5%) 321 (21.7%) 311 (26.2%) <0.0001 
Central Europe N (%) 258 (14.8%) 526 (27.2%) 832 (40.4%) 672 (45.5%) 538 (45.4%) <0.0001 
Asia-Pacific N (%) 441 (25.2%) 392 (20.3%) 317 (15.4%) 205 (13.9%) 132 (11.1%) <0.0001 
SBP Mean (SD) 102.18 (3.77) 112.66 (3.02) 122.76 (3.01) 132.45 (2.90) 147.73 (9.16) <0.0001 
DBP Mean (SD) 64.86 (7.31) 70.31 (7.63) 75.21 (7.93) 78.48 (8.33) 82.88 (10.00) <0.0001 
eGFR Mean (SD) 67.09 (20.86) 67.96 (20.80) 67.71 (20.28) 67.95 (18.74) 67.87 (19.21) 0.6947 
BNP 
Median 
(IQR) 
263.9 [157.7, 
520.8] 
251.0 [158.5, 
482.9] 
243.3 [145.6, 
455.2] 
243.9 [148.6, 
442.2] 
262.6 [161.4, 
447.4] 
0.0103 
NTproBNP 
Median 
(IQR) 
1765.0 [939.0, 
3520.0] 
1606.0 [893.0, 
3322.0] 
1597.5 [867.0, 
3140.0] 
1578.5 [836.0, 
3000.0] 
1600.0 [900.0, 
3120.0] 
0.3009 
HR Mean (SD) 71.26 (12.21) 72.09 (11.69) 72.70 (11.99) 73.33 (12.07) 72.57 (12.06) <0.0001 
BMI Mean (SD) 27.24 (5.41) 27.74 (5.46) 28.28 (5.41) 28.75 (5.52) 29.28 (5.66) <0.0001 
Creatinine (mg/dl) Mean (SD) 1.15 (0.30) 1.13 (0.29) 1.12 (0.30) 1.10 (0.30) 1.10 (0.30) <0.0001 
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Variable Statistic 
<110 
(N = 1747) 
110-<120 
(N = 1931) 
120-<130 
(N = 2059) 
130-<140 
(N = 1477) 
≥140 
(N = 1185) 
P value    
Ischaemic etiology N (%) 949 (54.3%) 1194 (61.8%) 1231 (59.8%) 923 (62.5%) 739 (62.4%) <0.0001 
HF duration 0-1 yrs N (%) 514 (29.4%) 562 (29.1%) 636 (30.9%) 468 (31.7%) 343 (28.9%) 0.3536 
>1-5 yrs N (%) 627 (35.9%) 752 (38.9%) 768 (37.3%) 580 (39.3%) 505 (42.6%) 0.0041 
>5 yrs N (%) 606 (34.7%) 617 (32.0%) 655 (31.8%) 429 (29.0%) 337 (28.4%) 0.0014 
Ejection fraction (%) Mean (SD) 27.58 (6.49) 28.84 (6.27) 30.01 (6.01) 30.62 (5.89) 31.03 (5.65) <0.0001 
NYHA I N (%) 111 ( 6.4%) 96 ( 5.0%) 80 ( 3.9%) 43 ( 2.9%) 59 ( 5.0%) <0.0001 
II N (%) 1315 (75.4%) 1396 (72.4%) 1402 (68.2%) 992 (67.2%) 814 (68.8%) <0.0001 
III N (%) 310 (17.8%) 431 (22.4%) 556 (27.1%) 428 (29.0%) 293 (24.8%) <0.0001 
IV N (%) 7 ( 0.4%) 5 ( 0.3%) 17 ( 0.8%) 14 ( 0.9%) 17 ( 1.4%) 0.0011 
KCCQ-Clinical Median (IQR) 82.3 [66.7, 93.8] 82.3 [65.6, 92.7] 79.2 [62.5, 91.7] 77.9 [60.4, 90.6] 78.1 [60.4, 91.1] <0.0001 
Hypertension N (%) 892 (51.1%) 1219 (63.1%) 1526 (74.1%) 1244 (84.2%) 1059 (89.4%) <0.0001 
Diabetes N (%) 503 (28.8%) 671 (34.7%) 709 (34.4%) 546 (37.0%) 478 (40.3%) <0.0001 
Atrial Fibrillation N (%) 605 (34.6%) 672 (34.8%) 795 (38.6%) 589 (39.9%) 430 (36.3%) 0.0031 
Prior HF Hospitalization N (%) 1081 (61.9%) 1223 (63.3%) 1333 (64.7%) 921 (62.4%) 716 (60.4%) 0.1265 
MI N (%) 725 (41.5%) 915 (47.4%) 877 (42.6%) 632 (42.8%) 485 (40.9%) 9e-04 
Stroke N (%) 151 ( 8.6%) 143 ( 7.4%) 194 ( 9.4%) 132 ( 8.9%) 105 ( 8.9%) 0.2340 
CABG N (%) 263 (15.1%) 343 (17.8%) 304 (14.8%) 217 (14.7%) 176 (14.9%) 0.0444 
PCI N (%) 385 (22.0%) 490 (25.4%) 430 (20.9%) 272 (18.4%) 224 (18.9%) <0.0001 
ACE inhibitor N (%) 1356 (77.6%) 1531 (79.3%) 1641 (79.7%) 1140 (77.2%) 864 (72.9%) 1e-04 
ARB N (%) 395 (22.6%) 408 (21.1%) 425 (20.6%) 334 (22.6%) 330 (27.8%) <0.0001 
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Variable Statistic 
<110 
(N = 1747) 
110-<120 
(N = 1931) 
120-<130 
(N = 2059) 
130-<140 
(N = 1477) 
≥140 
(N = 1185) 
P Value 
Diuretic N (%) 1403 (80.3%) 1538 (79.6%) 1656 (80.4%) 1202 (81.4%) 939 (79.2%) 0.6564 
Digoxin N (%) 601 (34.4%) 596 (30.9%) 640 (31.1%) 403 (27.3%) 299 (25.2%) <0.0001 
Beta-Blocker N (%) 1609 (92.1%) 1805 (93.5%) 1918 (93.2%) 1373 (93.0%) 1106 (93.3%) 0.5383 
Mineralocortoid N (%) 1082 (61.9%) 1140 (59.0%) 1154 (56.0%) 745 (50.4%) 550 (46.4%) <0.0001 
Anticoagulant N (%) 545 (31.2%) 603 (31.2%) 723 (35.1%) 471 (31.9%) 343 (28.9%) 0.0041 
Antiplatelet N (%) 999 (57.2%) 1122 (58.1%) 1116 (54.2%) 828 (56.1%) 671 (56.6%) 0.1435 
Lipid Lowering N (%) 988 (56.6%) 1117 (57.8%) 1134 (55.1%) 840 (56.9%) 650 (54.9%) 0.3568 
ICD N (%) 349 (20.0%) 343 (17.8%) 279 (13.6%) 160 (10.8%) 112 ( 9.5%) <0.0001 
CRT N (%) 181 (10.4%) 151 ( 7.8%) 134 ( 6.5%) 58 ( 3.9%) 50 ( 4.2%) <0.0001 
 
SBP – systolic blood pressure (mmHg) 
DBP – diastolic blood pressure (mmHg) 
eGFR - Estimated GFR (ml/min/1.73m2) 
HR- heart rate (bpm) 
BMI – body mass index (kg/m2) 
MI – myocardial infarction 
CABG – coronary artery bypass grafting 
PCI – percutaneous coronary intervention 
ACE – angiotensin converting enzyme 
ARB – angiotensin receptor blocker 
ICD- implantable cardioverter defibrillator 
CRT – cardiac resynchronization therapy 
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Table 2  
 
  Primary Endpoint CV Death 
 
SBP-
Group 
Treat Events Rate/100yrs (CI) HR (CI) P-value P for 
interaction 
Events Rate/100yrs 
(CI) 
HR (CI) P-value P for 
interaction 
 
All Enalapril 1117 13.2 (12.4, 13.9) 
0.80 (0.73-0.87) 
  693 7.5 (7.0, 8.1) 
0.80 (0.71-0.89) 0.0001 
 
 Sac/val 914 10.5 (9.8, 11.2)  558 6.0 (5.5, 6.5)  
<110 Enalapril 249 14.0 (12.3, 15.8) 
0.88 (0.74-1.06) 0.1918 
 164 8.6 (7.3, 10.0) 
0.84 (0.66-1.05) 0.1289 
 
 Sac/val 208 12.3 (10.7, 14.1)  130 7.1 (6.0, 8.5)  
110-<120 Enalapril 249 13.3 (11.7, 15.1) 
0.84 (0.70-1.01) 0.0579 
 148 7.2 (6.1, 8.5) 
0.88 (0.70-1.11) 0.2741 
 
 Sac/val 223 11.2 (9.7, 12.7)  136 6.3 (5.3, 7.5)  
120-<130 Enalapril 264 12.6 (11.1, 14.2) 
0.73 (0.61-0.87) 0.0006 
 173 7.7 (6.6, 8.9) 
0.65 (0.52-0.82) 0.0003 
 
 Sac/val 202 9.2 (8.0, 10.5)  118 5.0 (4.2, 6.0)  
130-<140 Enalapril 190 12.3 (10.7, 14.2) 
0.74 (0.59-0.92) 0.0058 
 116 6.9 (5.7, 8.3) 
0.79 (0.60-1.04) 0.0967 
 
 Sac/val 141 9.1 (7.6, 10.7)  90 5.5 (4.4, 6.7)  
>=140 Enalapril 165 13.6 (11.6, 15.9) 
0.81 (0.65-1.02) 0.0674 0.5542 
92 6.8 (5.5, 8.4) 
0.91 (0.68-1.22) 0.5368 0.3580 
 Sac/val 140 11.0 (9.2, 13.0) 84 6.2 (4.9, 7.7) 
 
 
  HF-Hospitalization Total Death 
 
SBP-
Group 
Treat Events Rate/100yrs (CI) HR (CI) P-value P for 
interaction 
Events Rate/100yrs 
(CI) 
HR (CI) P-value P for 
interaction 
All Enalapril 658 7.7 (7.2, 8.4) 
0.80 (0.71-0.89) 0.0001 
 835 9.0 (8.4, 9.7) 
0.84 (0.76-0.93) 0.0009 
 
 Sac/val 537 6.2 (5.6, 6.7)  11 7.6 (7.1, 8.2)  
<110 Enalapril 152 8.5 (7.2, 10.0) 
0.91 (0.71-1.15) 0.4455 
 195 10.2 (8.8, 11.7) 
0.85 (0.69-1.05) 0.1348 
 
 Sac/val 131 7.7 (6.5, 9.2)  158 8.7 (7.4, 10.2)  
110-<120 Enalapril 147 7.9 (6.7, 9.3) 
0.85 (0.67-1.07) 0.1666 
 186 9.1 (7.8, 10.5) 
0.84 (0.68-1.04) 0.1107 
 
 Sac/val 133 6.7 (5.6, 7.9)  164 7.6 (6.5, 8.9)  
120-<130 Enalapril 153 7.3 (6.2, 8.6) 
0.75 (0.59-0.95) 0.0192 
 203 9.0 (7.8, 10.4) 
0.75 (0.61-0.92) 0.0062 
 
 Sac/val 121 5.5 (4.6, 6.6)  159 6.8 (5.8, 7.9)  
130-<140 Enalapril 108 7.0 (5.8, 8.5) 
0.69 (0.51-0.93) 0.0138 
 142 8.4 (7.1, 9.9) 
0.83 (0.65-1.06) 0.1306 
 
 Sac/val 75 4.8 (3.8, 6.0)  115 7.0 (5.8, 8.4)  
>=140 Enalapril 98 8.1 (6.6, 9.9) 
0.75 (0.56-1.01) 0.0611 0.5753 
109 8.1 (6.6, 9.7) 
1.05 (0.81-1.37) 0.704 
 
0.4092  Sac/val 77 6.0 (4.8, 7.6) 115 8.5 (7.0, 10.2) 
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Table 3 Five unit fall from baseline in KCCQ clinical summary score at each in trial visit 
 
 
Variable Statistic 
<110 
E* 
(N = 913) 
<110 
S/V** 
(N = 834) 
110-<120 
E* 
(N = 941) 
110-<120 
S/V** 
(N = 990) 
120-<130 
E* 
(N = 1018) 
120-<130 
S/V** 
(N = 1041) 
130-<140 
E* 
(N = 746) 
130-<140 
S/V** 
(N = 731) 
≥140 
E* 
(N = 594) 
≥140 
S/V** 
(N = 591) 
 
 
Month 4 Nobs (Nmiss) 743 (170) 692 (142) 793 (148) 836 (154) 880 (138) 912 (129) 648 (98) 633 (98) 507 (87) 510 (81) 
Yes N (%) 210 (28.3%) 176 (25.4%) 212 (26.7%) 241 (28.8%) 233 (26.5%) 214 (23.5%) 172 (26.5%) 154 (24.3%) 138 (27.2%) 124 (24.3%) 
No N (%) 533 (71.7%) 516 (74.6%) 581 (73.3%) 595 (71.2%) 647 (73.5%) 698 (76.5%) 476 (73.5%) 479 (75.7%) 369 (72.8%) 386 (75.7%) 
 
 
Month 8 Nobs (Nmiss) 717 (196) 678 (156) 761 (180) 811 (179) 838 (180) 868 (173) 618 (128) 614 (117) 488 (106) 489 (102) 
Yes N (%) 229 (31.9%) 183 (27.0%) 246 (32.3%) 226 (27.9%) 262 (31.3%) 231 (26.6%) 181 (29.3%) 157 (25.6%) 149 (30.5%) 144 (29.4%) 
No N (%) 488 (68.1%) 495 (73.0%) 515 (67.7%) 585 (72.1%) 576 (68.7%) 637 (73.4%) 437 (70.7%) 457 (74.4%) 339 (69.5%) 345 (70.6%) 
 
 
Month 12 Nobs (Nmiss) 668 (245) 647 (187) 731 (210) 774 (216) 804 (214) 848 (193) 599 (147) 591 (140) 463 (131) 469 (122) 
Yes N (%) 220 (32.9%) 170 (26.3%) 227 (31.1%) 234 (30.2%) 248 (30.8%) 243 (28.7%) 181 (30.2%) 179 (30.3%) 139 (30.0%) 147 (31.3%) 
No N (%) 448 (67.1%) 477 (73.7%) 504 (68.9%) 540 (69.8%) 556 (69.2%) 605 (71.3%) 418 (69.8%) 412 (69.7%) 324 (70.0%) 322 (68.7%) 
 
 
Month 24 Nobs (Nmiss) 359 (554) 377 (457) 401 (540) 440 (550) 502 (516) 494 (547) 365 (381) 366 (365) 287 (307) 300 (291) 
Yes N (%) 123 (34.3%) 119 (31.6%) 154 (38.4%) 133 (30.2%) 152 (30.3%) 152 (30.8%) 137 (37.5%) 108 (29.5%) 104 (36.2%) 90 (30.0%) 
No N (%) 236 (65.7%) 258 (68.4%) 247 (61.6%) 307 (69.8%) 350 (69.7%) 342 (69.2%) 228 (62.5%) 258 (70.5%) 183 (63.8%) 210 (70.0%) 
 
 
Month 36 Nobs (Nmiss) 114 (799) 125 (709) 152 (789) 158 (832) 210 (808) 188 (853) 138 (608) 138 (593) 126 (468) 114 (477) 
Yes N (%) 46 (40.4%) 42 (33.6%) 71 (46.7%) 47 (29.7%) 71 (33.8%) 60 (31.9%) 55 (39.9%) 60 (43.5%) 46 (36.5%) 45 (39.5%) 
No N (%) 68 (59.6%) 83 (66.4%) 81 (53.3%) 111 (70.3%) 139 (66.2%) 128 (68.1%) 83 (60.1%) 78 (56.5%) 80 (63.5%) 69 (60.5%) 
 
 
End of study Nobs (Nmiss) 680 (233) 637 (197) 715 (226) 752 (238) 809 (209) 834 (207) 574 (172) 579 (152) 451 (143) 450 (141) 
Yes N (%) 319 (46.9%) 251 (39.4%) 315 (44.1%) 282 (37.5%) 357 (44.1%) 317 (38.0%) 253 (44.1%) 229 (39.6%) 198 (43.9%) 211 (46.9%) 
No N (%) 361 (53.1%) 386 (60.6%) 400 (55.9%) 470 (62.5%) 452 (55.9%) 517 (62.0%) 321 (55.9%) 350 (60.4%) 253 (56.1%) 239 (53.1%) 
 
*E=enalapril **S/V=sacubitril/valsartan 
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Table 4 Adverse Events during Randomized Treatment 
 
 
 
Variable  
<110 
             E* 
          (N = 913) 
<110 
S/V** 
(N = 834) 
110-<120 
E*  
(N = 941) 
110-<120 
S/V**  
(N = 990) 
120-<130 120-<130 130-<140 
E* S/V** E* 
(N = 1018)  (N = 1041)  (N = 746) 
130-<140 
S/V** 
 (N = 731) 
≥140 
E*  
(N = 594) 
≥140 
S/V** 
(N = 591) 
 
P value 
Symptomatic 
Hypotension 
N (%) 
125 
(13.7%) 
213 
(25.5%) 
101 
(10.7%) 
143 
(14.4%) 
87 ( 8.5%) 
119 
(11.4%) 
50 ( 6.7%) 66 ( 9.0%) 25 ( 4.2%) 
47 ( 
8.0%) 
<0.0001 
Symptomatic 
Hypotension 
SBP <90mmHg 
 
N (%) 
 
26 ( 2.8%) 
 
59 ( 7.1%) 
 
18 ( 1.9%) 
 
25 ( 2.5%) 
 
10 ( 1.0%) 
 
15 ( 1.4%) 
 
5 ( 0.7%) 
 
9 ( 1.2%) 
 
0 ( 0.0%) 
 
4 ( 0.7%) 
 
<0.0001 
Creatinine >= 
2.5 mg/dL 
N (%) 42 ( 4.6%) 32 ( 3.8%) 47 ( 5.0%) 25 ( 2.5%) 46 ( 4.5%) 42 ( 4.0%) 26 ( 3.5%) 17 ( 2.3%) 27 ( 4.5%) 
23 ( 
3.9%) 
0.0637 
Creatinine > 3.0 
mg/dL 
N (%) 15 ( 1.6%) 13 ( 1.6%) 22 ( 2.3%) 11 ( 1.1%) 17 ( 1.7%) 18 ( 1.7%) 15 ( 2.0%) 10 ( 1.4%) 14 ( 2.4%) 
11 ( 
1.9%) 
0.6590 
Potassium > 5.5 
mmol/L 
N (%) 
149 
(16.3%) 
114 
(13.7%) 
146 
(15.5%) 
152 
(15.4%) 
201 
(19.7%) 
203 
(19.5%) 
136 
(18.2%) 
118 
(16.1%) 
102 
(17.2%) 
94 
(15.9%) 
0.0089 
Potassium > 6.0 
mmol/L 
N (%) 39 ( 4.3%) 28 ( 3.4%) 53 ( 5.6%) 40 ( 4.0%) 64 ( 6.3%) 51 ( 4.9%) 51 ( 6.8%) 31 ( 4.2%) 29 ( 4.9%) 
31 ( 
5.2%) 
0.0306 
Cough N (%) 
164 
(18.0%) 
133 
(15.9%) 
145 
(15.4%) 
118 
(11.9%) 
127 
(12.5%) 
100 ( 
9.6%) 
99 (13.3%) 69 ( 9.4%) 66 (11.1%) 
54 ( 
9.1%) 
<0.0001 
Angioedema             
No 
treatment/antihista
mines only 
N (%) 4 ( 0.4%) 1 ( 0.1%) 2 ( 0.2%) 2 ( 0.2%) 0 ( 0.0%) 4 ( 0.4%) 0 ( 0.0%) 2 ( 0.3%) 0 ( 0.0%) 2 ( 0.3%) 0.3498 
Catecholamines/ 
corticosteroids 
without 
hospitalization 
N (%) 1 ( 0.1%) 0 ( 0.0%) 1 ( 0.1%) 1 ( 0.1%) 1 ( 0.1%) 2 ( 0.2%) 1 ( 0.1%) 0 ( 0.0%) 0 ( 0.0%) 3 ( 0.5%) 0.3010 
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Hospitalized/no 
airway compromise  
N (%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 2 ( 0.2%) 0 ( 0.0%) 1 ( 0.1%) 0 ( 0.0%) 0 ( 0.0%) 1 ( 0.2%) 0 ( 0.0%) 0.3472 
Airway 
compromise 
N (%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%) 0 ( 0.0%)      - 
*E=enalapril **S/V=sacubitril/valsartan 
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Suppl. Figure 9 - Systolic blood pressure 4 months after baseline
Logrank P = 0.0137
 
Logrank P < 0.001
 
Logrank P = 0.1095
 
Logrank P < 0.001
 
Logrank P = 0.0195
 
Logrank P = 0.0028
 
